Delayed immune-related adverse events profile associated with immune checkpoint inhibitors: a real-world analysis
Our pharmacovigilance analysis indicates that a small percentage of patients receiving ICIs therapy experience delayed irAEs, which are challenging to manage and may result in severe consequences. Prompt identification and intervention of these delayed irAEs are crucial in clinical practice.
Authors
- Kathy Qian Luo (ORCID: https://orcid.org/0000-0001-7454-9547)
- Jing Tian (ORCID: https://orcid.org/0000-0003-0741-8031)
- Yana Yang (ORCID: https://orcid.org/0000-0001-9763-2845)
- Linman Li (ORCID: https://orcid.org/0000-0002-2757-7083)
- Lei Ma (ORCID: https://orcid.org/0009-0002-0386-5731)
- Yan Luo
- Yaoxin Wu (ORCID: https://orcid.org/0009-0009-2857-4245)
Institutions
- Chongqing University (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Cancer Hospital (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-11-11
- DOI
- https://doi.org/10.3389/fphar.2024.1453429
- Citations
- 10
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.83